# RATIONALE-301 (NCT03412773)

> A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

No report yet. It can be ordered.

- Drugs tested: tislelizumab
- Indication: first-line unresectable hepatocellular carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03412773
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: BeiGene
- Conditions: Hepatocellular Carcinoma (HCC)
- Interventions: Tislelizumab; Sorafenib
- Enrollment: 684
- Primary outcome: Safety Run-in Sub-study: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
- Primary outcome: Safety Run-in Sub-study: Serum Concentration of Tislelizumab
- Primary outcome: Main Study: Overall Survival (OS)

## Indexed commentary on RATIONALE-301 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 13
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=rationale-301-nct03412773

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03412773", "email": "<work email>"}; the inbox owner confirms by the emailed link.